Lamotrigine is NOT Recommended for Post-COVID Headaches
Lamotrigine should not be used for post-COVID headaches. There is no evidence supporting its efficacy for this indication, and established treatments with proven effectiveness are available.
Evidence-Based Treatment Approach for Post-COVID Headache
First-Line Acute Treatment
Based on the most recent migraine guideline 1 and real-world post-COVID headache data, the treatment algorithm should be:
Step 1: NSAIDs or Acetaminophen
- Start with ibuprofen 400mg or naproxen as first-line acute treatment 1
- Acetaminophen 1000mg if NSAIDs are contraindicated 1
- Dexketoprofen showed 58.8% pain-freedom at 2 hours in post-COVID headache patients 2
- Ibuprofen achieved 54.3% pain-freedom response in post-COVID patients 2
Step 2: Add Triptan if Inadequate Response
- Combine a triptan with an NSAID for moderate-to-severe headache 1
- Triptans achieved 57.7% pain-freedom in post-COVID headache patients 2
- This combination is superior to monotherapy for migraine-like post-COVID headaches
Step 3: Consider Indomethacin for Refractory Cases
- Indomethacin is highly effective for refractory post-COVID headache 3
- In a study of 37 patients with headache refractory to usual analgesics and triptans, 97% (36/37) reported >50% relief by day 3 3
- 5 patients became completely asymptomatic by day 5 3
Preventive Treatment (When Needed)
Post-COVID headache often requires preventive therapy, with 75% of patients needing it 2.
First-Line Preventive: Amitriptyline
- Amitriptyline is the most effective preventive option with real-world evidence 2, 4
- Achieved 45.5% responder rate (≥50% reduction in headache days) 2
- Mean reduction of 9.6 headache days per month (95% CI: 6.5-12.7) 4
- Start at 10-25mg at bedtime, titrate based on response
- Better response predicted by: history of tension-type headache and absence of nausea 4
- Only 5% discontinuation rate due to side effects 4
Alternative Preventive Options:
- OnabotulinumtoxinA: 18.2% achieved ≥75% reduction in headache days 2
- Anesthetic nerve blocks: 38.9% achieved ≥50% response 2
- Mirtazapine: 50% responder rate in small numbers 2
Why NOT Lamotrigine?
Lack of Evidence for Post-COVID Headache
- Zero studies exist evaluating lamotrigine for post-COVID headache
- None of the COVID-19 management guidelines 5, 6, 5, 7 mention lamotrigine for headache
Limited Evidence Even for Primary Headaches
The available lamotrigine evidence is restricted to:
- Migraine with aura prophylaxis: One small open-label study (n=24) from 1999 8
- SUNCT syndrome: Case reports and observational studies only 9
- Trigeminal neuralgia: Most effective indication, but not relevant here 10
- Sturge-Weber syndrome: Single case report 11
Practical Disadvantages
- Requires slow titration (starting 25mg/day, increasing by 25mg increments) to minimize Stevens-Johnson syndrome risk 9
- Takes weeks to months to reach therapeutic effect
- Post-COVID headache patients need rapid relief, not prolonged titration
Clinical Phenotype Context
Post-COVID headache typically presents as:
- Migraine-like in 64.8% of de novo cases 12
- Holocranial (63%), frontal (48%), pressing quality (75%) 2
- Moderate intensity (7/10), with photophobia (58%) 2
- 16.2% develop persistent de novo headache at 2 years 12
This phenotype responds to migraine-specific treatments (triptans, NSAIDs, amitriptyline), not anticonvulsants like lamotrigine.
Recommended Algorithm
For Acute Post-COVID Headache:
- NSAID (ibuprofen 400mg or dexketoprofen) ± acetaminophen
- If inadequate → Add triptan to NSAID
- If refractory → Indomethacin 25-50mg TID
For Persistent/Frequent Post-COVID Headache (≥4 days/month):
- Amitriptyline 10-25mg qHS, titrate to 50-75mg
- If contraindicated/ineffective → Consider onabotulinumtoxinA or nerve blocks
- Avoid opioids and butalbital 1
Critical Pitfall: Do not delay effective treatment by attempting unproven therapies like lamotrigine when evidence-based options (NSAIDs, triptans, amitriptyline, indomethacin) have demonstrated efficacy specifically in post-COVID headache populations.